VENUS®
Enjoy Innovations

VRL/SEC/NSE

18.05.2013

National Stock Exchange of India Ltd.
5th Floor , Exchange Plaza
Bandra (E),
Mumbai- 400 051

Sub.: Audited Annual Financial Results for the year ended on 31.03.2013 .

Dear Sir/Madam,

Please find enclosed herewith copy of Audited Financial Results for the quarter ended on 31.03.2013 and Annual Audited Financial Results for the year ended on 31.03.2013 which were taken on record by the Board of Directors at its meeting held on 18.05.2013.

Kindly acknowledge the receipt.

Thanking you.

Yours faithfully,
for VENUS REMEDIES LIMITED

Neha Kodan
(Company Secretary)

VENUS®
Enjoy Innovations

AUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED 31st March, 2013

(Rs. In Millions)

S. No.	PARTICULARS	Quarter Ended on			Year Ended on	
	Part – I	31/03/2013 Audited	31/12/2012 Unaudited	31/03/2012 Unaudited	31/03/2013 Audited	31/03/2012 Audited
1	**Net Sales/ Income from operations**					
	Gross Sales	1253.11	1119.09	1137.15	4,602.58	4,023.91
	Less : Excise Duty	2.83	2.85	2.44	11.61	7.38
	(a) Net Sales	1250.28	1116.24	1134.71	4,590.97	4,016.53
	(b) Other Operating Income	2.89	10.12	12.21	22.41	35.34
	Total Income from Operation (Net)	**1,253.17**	**1,126.36**	**1,146.92**	**4,613.38**	**4,051.87**
2	**Expenses**					
	(a) Consumption of raw materials	785.68	635.35	646.48	2,725.58	2,350.71
	(b) (Increase)/ Decrease in stock in trade	-31.83	0.55	0.21	-92.93	-90.33
	(c) Employee benefits expense	58.87	58.35	55.79	232.38	205.78
	(d) Other expenses	139.68	133.09	161.78	563.47	524.69
	Total expense	**952.40**	**827.34**	**864.26**	**3,428.50**	**2,990.85**
	EBIDTA	**300.77**	**299.02**	**282.66**	**1,184.88**	**1,061.02**
	Depreciation & amortisation expense	80.07	80.09	61.31	317.62	240.67
	Profit after Depreciation & Amortisation Expenses	220.70	218.93	221.35	867.26	820.35
3	**Profit from operations before other income , finance costs and exceptional items (1-2)**	**220.70**	**218.93**	**221.35**	**867.26**	**820.35**
4	Other income	-3.45	3.45	2.01	3.95	3.80
5	**Profit before finance costs and exceptional items (3+4)**	**217.25**	**222.38**	**223.36**	**871.21**	**824.15**
6	Finance Costs	61.68	52.94	72.60	244.49	272.64
7	**Profit after finance costs but before exceptional items (5-6)**	**155.57**	**169.44**	**150.76**	**626.72**	**551.51**
8	Exceptional items	0.00	0.00	0.00	00.00	00.00
9	**Profit from ordinary activities before tax (7+8)**	**155.57**	**169.44**	**150.76**	**626.72**	**551.51**
10	Tax expense	36.04	8.89	-4.84	55.27	51.22
11	**Profit from ordinary activities after tax (9-10)**	**119.53**	**160.55**	**155.60**	**571.45**	**500.29**
12	Exceptional items (net of tax expense	00.00	00.00	0.00	0.00	0.00
13	**Net profit for the period (11-12)**	**119.53**	**160.55**	**155.60**	**571.45**	**500.29**
14	**Paid up Equity Share Capital**	**105.42**	**97.42**	**97.42**	**105.42**	**97.42**
15	**Reserves excluding revaluation reserves**	**N. A.**	**N. A.**	**N. A.**	**3,769.22**	**3,003.48**
16	**E.P.S - Basic not annualised for the qtr**	**11.34**	**16.48**	**15.97**	**54.21**	**51.35**
	- Annualised	**45.35**	**65.92**	**63.89**	**54.21**	**51.35**
	Part – II					
1	**Public Shareholding**					
	- Number of Shares	6437086	6388986	6388986	6437086	6388986
	- Percentage of Shareholding	61.06	65.58	65.58	61.06	65.58
2	**Promoters and promoter group shareholding**					
	a) Pledged as collateral security to bank					
	- Number of Shares	1930000	1930000	1930000	1930000	1930000
	- Percentage of shares (as a % of the total share holding of promoter and promoter group	47.02	57.56	57.56	47.02	57.56
	- Percentage of shares (as a % of the total share capital	18.31	19.81	19.81	18.31	19.81
	b) Non-Encumbered					
	- Number of Shares	2174902	1423002	1423002	2174902	1423002
	- Percentage of shares (as a % of the total share holding of promoter and promoter group	52.98	42.44	42.44	52.98	42.44
	- Percentage of shares (as a % of the total share capital	20.63	14.61	14.61	20.63	14.61

Particulars	3 months ended 31.03.2013
(B) INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	NIL
Received during the quarter	3
Disposed of during the quarter	3
Remaining unresolved at the end of the quart	NIL

For VENUS REMEDIES LIMITED

CHAIRMAN & MANAGING DIRECTOR

VENUS®
Enjoy Innovations

Notes:

1. The above Audited financial Results of the Company for the year ended 31.03.2013 reviewed by the Audit Committee and taken on record at the Board Meeting on May 18, 2013.

2. During the Quarter:

   a) Company launched world's first anti stress product EZENUS in easy to use herbal candy which is absolute safe, zero calorie and non addictive with clinically proven anti stress activity.

   B)Venus Remedies' MEROPENEM receives market authorization in Mexico.

   c) Venus sign Exclusive Marketing Rights deal for its novel Antibiotic Ajuvant Entity to South Africa's second largest Pharmaceutical Company - Adcock

   d) Venus Remedies bags Australian GMP from TGA for four of its facilities.

   e) Venus Remedies launches 'Elores' - CSE 1034, a US Patent protected product in India

3. During the quarter three investor grievances were received and resolved. No investor grievance was pending at the end of the quarter.

4. The figures of last quarter are the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the current financial year.

5. The Company caters to only one segment i.e. "Pharmaceutical Formulations".

For and on behalf of Board of Directors
For VENUS REMEDIES LIMITED

(Pawan Chaudhary)
Chairman & Managing Director

Place : Panchkula
Date : 18.05.2013

VENUS®
Enjoy Innovations

Standalone Statement of Assets and Liabilities

Clause 41 of the Listing Agreement For Companies (Other than Banks)

	Particulars	Year Ended on 03/31/2013	Year Ended on 03/31/2012
		(Rs.` In Millions)	(Rs.` In Millions)
A	**EQUITY AND LIABILITIES**		
1	**Shareholders' funds**		
	(a) Share capital	105.42	97.42
	(b) Reserves and surplus	3769.22	3003.48
	(c) Money received against share warrants	47.74	90.19
	Sub-total – Shareholders' funds	3922.38	3191.09
2	**Non-current liabilities**		
	(a) Long-term borrowings	1291.15	991.33
	(b) Deferred tax liabilities (net)	146.81	116.39
	(c) Other long-term liabilities	4.66	2.27
	(d) Long-term provisions	29.14	24.99
	Sub-total – Non-current liabilities	1471.76	1134.98
3	**Current liabilities**		
	(a) Short-term borrowings	956.81	832.43
	(b) Trade payables	178.7	123.28
	(c) Other current liabilities	578.83	432.24
	(d) Short-term provisions	186.29	153.34
	Sub-total – Current liabilities	1900.63	1541.29
	TOTAL – EQUITY AND LIABILITIES	7294.77	5867.36
B	**ASSETS**		
1	**Non-current assets**		
	(a) Fixed assets	4287.25	3588.64
	(b) Non-current investments	287.36	287.36
	(c) Long-term loans and advances	427.4	260.07
	Sub-total – Non-current assets	5002.01	4136.07
2	**Current assets**		
	(a) Current investments		
	(b) Inventories	1263.97	961.91
	(c) Trade receivables	531.13	443.26
	(d) Cash and cash equivalents	62.59	29.12
	(e) Short-term loans and advances	435.07	297.00
	Sub-total – Current assets	2292.76	1731.29
	TOTAL – ASSETS		

For VENUS REMEDIES